Synopsis:
Despite the implementation of the treat-to-target approach and recent advancements in biological therapy of rheumatoid arthritis there are still unmet needs that have to be dealt with.
This symposium will focus on identifying these gaps and exploring potential strategies to address them.
One promising approach involves therapies targeting interleukin-6 (IL-6), including inhibition of the IL-6 ligand.
The presenters will share insights from clinical trials and real-world studies of olokizumab, a novel direct IL-6 inhibitor that may become an important tool in the hands of rheumatologists.
Agenda:
|
|
Chairperson: Prof. Kunihiro Yamaoka
|
|
11:10-11:15 |
Welcome Remarks: Introduction
|
|
11:15-11:30 |
Unmet Needs in Rheumatoid Arthritis Management
Prof. Josef S. Smolen |
|
11:30-11:45 |
Olokizumab in the Landscape of IL-6 Inhibition
Prof. Kunihiro Yamaoka |
|
11:45-12:00 |
Building the bridge between RCTs and real-world experience
Dr Roy M. Fleischmann |
|
12:00-12:15 |
Closing Remarks: Q&A and Discussion
All |
